

RECEIVED
CENTRAL FAX CENTER

MAY 19 2008

Certificate of Facsimile for U.S. Application No. 10/037718

Inventors: MCGINNIS, et al,
Title: "Two-Dimensional Linkage Study Methods and Related Inventions"
U.S. Application No. 10/037718, Date of filing: 4 January 2002

The following enclosed items are being faxed by me, Robert McGinnis, today May 19, 2008 to the Commissioner for Patents, USPTO Central Fax number, 571-273-8300. **Appropriate fee payment under 37 CFR 1.97(c)(2) and 37 CFR 1.17(p) using Credit Card PTO Form 2038 will be faxed separately.**

Enclosed Items:

- 1) **Supplemental Information Disclosure Statement (IDS)** with Remarks, signed, 4 sheets.
- 2) IDS document listing, Forms PTO/SB/08b (two sheets), PTO/SB/08a (one sheet; subtotal of 3 sheets).
- 3) Copies documents E1-E4 inclusive: E1 (12 sheets): LINDLÖF M ET AL: ANNALS OF HUMAN GENETICS. OCT 1987, vol. 51 (Pt 4), October 1987 (1987-10), pages 317-328; E2 (8 sheets): RAMSAY MICHELE ET AL: HUMAN MOLECULAR GENETICS, vol. 2, no. 7, 1993, pages 1007-1014; E3 (12 sheets): DEVLIN B ET AL: GENOMICS, vol. 29, no. 2, 1995, pages 311-322; E4 (5 sheets): COLLINS A ET AL: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE U.S.A., vol. 95, no. 4, 17 February 1998 (1998-02-17), pages 1741-1745; subtotal of 37 sheets.

Total of 44 sheets.

Respectfully submitted,

/Robert O. McGinnis/

Robert O. McGinnis

Reg. No. 44, 232

May 19, 2008

1575 West Kagy Blvd., Bozeman, MT. 59715

ph. 406-522-9355

Supplemental Information Disclosure Statement (IDS) for U.S. Appl. No. 10/037718 (Atty. Docket No. 2DLSM&R12/01), May 2008. This IDS contains references cited in the EPO for a related application.

**RECEIVED
CENTRAL FAX CENTER**

MAY 19 2008

In the United States Patent and Trademark Office

In re application of:

Inventors: MCGINNIS, Ralph Evan and
MCGINNIS, Robert Owen

Title of the Invention: "Two-Dimensional Linkage Study Methods and Related Inventions"

U.S. Application No. 10/037718

Date of filing: 4 January 2002

Patent application 10/037718 is a continuation-in-part of U.S. Patent Application 09/947,768 (filed 5 SEPT 2001), now abandoned. And 09/947,768 claims priority from US Provisional 60/230570 (filed 9/5/2000). Patent Application 09/947,768 is a continuation-in-part of U.S. Patent Application 09/623,068 (filed 26 AUG 2000). The present patent application is also a continuation-in-part of Patent Application 09/623,068 (filed 26 AUG 2000). Application 09/623,068 claims priority from PCT/US99/04376 filed (2/26/99). PCT/US99/04376 claims priority from US Provisional applications: 60/076182 filed 27Feb1998, 60/086947 filed 27May1998, 60/076102 filed 26 Feb 1998 and 60107673 filed 7 Nov 1998.

Art unit: 1631

Examiner: Whaley, Pablo

Supplemental Information Disclosure Statement

Supplemental Information Disclosure Statement (IDS) for U.S. Appl. No. 2
10/037718 (Atty. Docket No. 2DLSM&R12/01), May 2008. This IDS contains
references cited in the EPO for a related application.

c/o Honorable Commissioner of Patents
Washington, D.C.

RECEIVED
CENTRAL FAX CENTER
MAY 19 2008

Sir:

Attached hereto is Form PTO/SB/08B (2 sheets) and Form PTO/SB/08A (1 sheet) listing documents believed relevant to the subject application. **These documents include references cited in the EPO for a related application (EP 99 90 9679) since the filing (April 2002) of the original Information Disclosure Statement (IDS) for the present application.** This Supplemental IDS is filed under 37 CFR 1.97(c)(2) and an appropriate fee under 37 CFR 1.17(p) will be submitted separately.

It is respectfully requested that these documents be considered by the new Examiner and an initialed copy of each form be returned to the undersigned. It is also respectfully requested that the documents in the earlier IDS of April 2002, the Supplemental Amended IDS of March 2004, and the Supplemental IDS of November 2005 be considered by the new Examiner and an initialed copy of each form be returned to the undersigned. The previous record shows the Supplemental Amended IDS of March 2004 contains all the references in the original IDS of April 2002, with the addition of four references X-Z & AA at the end of PTO Form SB 08b listing. As explained in the Supplemental Amended IDS of March 2004, the applicants also amended PTO Form SB 08b slightly and deleted the term "PRIOR" from the heading "OTHER PRIOR ART-NON PATENT LITERATURE," so the amended heading reads "OTHER ART-NON PATENT LITERATURE."

This disclosure statement should not be construed as a representation that a search has been made or that no other material information as defined in 37 C.F.R. 1.56 (a) or similar requirements exists.

Supplemental Information Disclosure Statement (IDS) for U.S. Appl. No. 10/037718 (Atty. Docket No. 2DLSM&R12/01), May 2008. This IDS contains references cited in the EPO for a related application. 3

It is believed that this disclosure complies with the requirements of 37 C.F.R. 1.56, 1.97, 1.98 and the M.P.E.P. 609 and similar requirements. If for some reason the examiner considers otherwise, it is respectfully requested that the undersigned be notified.

Nonpatent documents E1-E4, D1-D4, A1-A5, ISR and ESR are listed in this Supplemental IDS. A copy of documents E1-E4, D1-D4, A1-A5, ISR and ESR is enclosed or will be sent separately. Some of the documents may have markings thereon. No significance is meant to be attached to the markings. Documents E1-E4 and D1-D4, were cited during the search or examination in the EPO for a related foreign application (EP 99 90 9679). Reference D1 (the Chee reference) is cited in the present application in endnote paragraphs [0341] and [0345] in connection with "Oligonucleotide Technology" described in paragraphs [0248] and [0249] in the present application. Documents A1-A5 are documents that are known to the applicants that are similar to documents D1-D4. These nonpatent documents E1-E4, D1-D4, A1-A5, ISR and ESR documents are not necessarily analogous art.

Patent documents EP1-EP3 are listed in this Supplemental IDS. A copy of documents EP1-EP3 is enclosed or will be sent separately. Some of the documents may have markings thereon. No significance is meant to be attached to the markings. These documents were cited during the search or examination in the EPO for a related foreign application (EP 99 90 9679). These patent documents EP1-EP3 are not necessarily analogous art.

Supplemental Information Disclosure Statement (IDS) for U.S. Appl. No. 10/037718 (Atty. Docket No. 2DLSM&R12/01), May 2008. This IDS contains references cited in the EPO for a related application. 4

A copy of the Supplementary Partial European Search Report (Document ESR) for related foreign application (EP 99 90 9679) is enclosed. A copy of each of the documents cited in the Supplementary Partial European Search Report, E1-E4 and EP2-EP3, is included or will be sent separately. Two references cited in the Supplementary Partial European Search Report were previously made of record in the previous IDSs for the present application; a copy these two references is enclosed or will be sent separately as a courtesy to the Examiner. The two references are (1) RE McGinnis Annals of Human Genetics vol. 62 (Pt 2) (1998), pp. 159-179 and (2) patent document EP2, EPO 0 892 068.

A copy of the International Search Report (ISR) for parent application PCT/US99/04376 is included herewith as Document ISR. This ISR was authored by the previous Examiner for the present application, Examiner Horlick. The references cited in the ISR, four published papers authored by Krugkyak, were made of record in the earlier filed IDSs for the present application. Some of these Krugkyak references are discussed in the Background of the present application.

Respectfully submitted,

/Robert O. McGinnis/

Robert O. McGinnis

Reg. No. 44, 232

May 17, 2008

1575 West Kagy Blvd., Bozeman, MT. 59715

ph. 406-522-9355

Enclosures: IDS document listing, Forms PTO/SB/08b (two sheets), PTO/SB/08a (one sheet), copies documents E1-E4 inclusive.

To follow separately: Copies of documents D1-D4, A1-A5, EP1-EP3 inclusive and documents ISR and ESR; Credit Card Form PTO 2038 with payment of fee under 37 CFR 1.17(p).